上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2015年
7期
73-76
,共4页
罕见病用药%罕见病%新药
罕見病用藥%罕見病%新藥
한견병용약%한견병%신약
orphan drugs%rare disease%new drugs
罕见病用药的研发能够得到政府政策和财力的支持，同样可使制药公司获得超额利润。随着罕见病用药市场的急剧增长，世界各大制药公司亦纷纷加入罕见病用药的研发行列。本文就美国FDA 2014年1-9月批准的罕见病用药情况作一概要介绍。
罕見病用藥的研髮能夠得到政府政策和財力的支持，同樣可使製藥公司穫得超額利潤。隨著罕見病用藥市場的急劇增長，世界各大製藥公司亦紛紛加入罕見病用藥的研髮行列。本文就美國FDA 2014年1-9月批準的罕見病用藥情況作一概要介紹。
한견병용약적연발능구득도정부정책화재력적지지，동양가사제약공사획득초액리윤。수착한견병용약시장적급극증장，세계각대제약공사역분분가입한견병용약적연발행렬。본문취미국FDA 2014년1-9월비준적한견병용약정황작일개요개소。
Pharmaceutical companies have obtained excessive profits from the policy and funding of various governments specially for the R&D of orphan drugs. The global pharmaceutical giants have joined in the ranks of orphan drugs R&D with the rapid growth of the market for the medication of rare diseases. This paper introduces the proifle of orphan drugs approved by FDA from January to September in 2014.
